Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drospirenone vs Norethindrone for Postpartum Hypertension in Preeclampsia
NCT07293728Phase 4Not yet recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of drospirenone in preeclampsia and hypertension (HTN) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Blood Pressure at 6 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
drospirenone
03
Conditions
preeclampsiahypertension (HTN)
Beyond the preview
Go deeper on NCT07293728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293728.